Travatan Z Shortage: What Providers and Prescribers Need to Know in 2026

Eye care providers are increasingly fielding calls from glaucoma patients who cannot fill their travoprost prescriptions at their usual pharmacy. While travoprost is not in a national FDA-declared shortage as of 2026, localized pharmacy-level gaps — driven by distributor delays, manufacturer transitions, and inventory inefficiencies — are real and growing in frequency. This clinical overview addresses what prescribers need to know to manage these situations proactively.

Current Supply Landscape (2026)

Travoprost 0.004% ophthalmic solution has a robust generic manufacturing base as of 2026. Established producers include Mylan, Lupin, Apotex, and Glenmark (which introduced an ionic-buffered preservative formulation in 2024). Alembic received final FDA approval in December 2025, and Sagent entered the market in 2025 as well. Brand-name Travatan Z (Sandoz/Novartis) remains available.

The FDA's drug shortage database does not currently list travoprost. However, anecdotal reports from patients and pharmacy staff consistently describe difficulty locating specific generic brands at individual pharmacies. This gap between national supply adequacy and local accessibility is the core clinical problem for providers to manage.

Clinical Consequences of Missed Travoprost Doses

Travoprost's IOP-lowering effect begins approximately 2 hours after instillation and peaks at 12 hours. IOP reduction is sustained over a 24-hour cycle, but this sustained suppression depends on consistent daily dosing. Missed doses allow IOP to return toward baseline — a particular concern for patients with:

• Advanced glaucomatous damage (small margin for IOP fluctuation)
• Normal-tension glaucoma (highly sensitive to small IOP changes)
• High-risk patients with thin corneas, large cup-to-disc ratio, or prior rapid progression

For these patients, even 3–5 days off medication carries potential clinical significance. A proactive switching protocol — rather than waiting for the patient to call in crisis — is recommended.

First-Line Alternative: Latanoprost

For most patients on travoprost who cannot access the medication, latanoprost 0.005% is the recommended bridge:

• Same drug class (prostaglandin analog), same mechanism of action (FP receptor agonist, uveoscleral outflow)
• Comparable IOP reduction: 6–8 mmHg in clinical trials (vs. 7–8 mmHg for travoprost) — no clinically meaningful difference for most patients
• Same once-daily evening dosing; no titration required
• Generic is universally available and costs $8–15/bottle at most pharmacies with GoodRx

A bridging prescription for latanoprost can be sent electronically the same day with a note to recheck IOP at the next scheduled visit. Most patients will not require dosage adjustment.

Other Prescribing Considerations by Patient Profile

Patient-specific factors may favor a different alternative:

• Concurrent ocular surface disease or severe dry eye: Consider tafluprost (Zioptan) — the only preservative-free prostaglandin analog. Particularly important if the patient was already benefiting from Travatan Z's sofZia preservative.
• Very high IOP requiring maximum prostaglandin effect: Consider bimatoprost 0.01% (generic Lumigan) — some meta-analyses show 1–2 mmHg additional IOP reduction vs. travoprost or latanoprost.
• Patients intolerant of prostaglandin-class side effects: Timolol 0.5% twice daily (if no pulmonary or cardiac contraindications), brimonidine 0.1–0.2% twice daily, or a fixed-combination product may be appropriate.
• Drop aversion or compliance challenges: Consider bimatoprost intracameral implant (Durysta) for eligible pseudophakic patients, or referral for laser trabeculoplasty (SLT) as a procedure-based alternative to daily drops.

Critical Note: Do Not Prescribe Two Prostaglandins Simultaneously

Patients should not use two prostaglandin analogs concurrently. Combined use of two or more ophthalmic prostaglandins (e.g., travoprost + latanoprost) may decrease the IOP-lowering effect or cause paradoxical IOP elevations due to receptor competition or downregulation. Always discontinue travoprost before initiating another prostaglandin analog.

Workflow Recommendations for Your Practice

To reduce the frequency of travoprost availability crises for your patients:

1. Prescribe 90-day supplies when possible and encourage mail-order pharmacy enrollment through the patient's insurance plan.
2. At each visit, verify the patient is filling their prescription without difficulty. Proactive check-in catches problems before they become emergencies.
3. Prepare a standing alternative prescription order (e.g., latanoprost 0.005% QD OU) for patients on travoprost, so staff can send it immediately if the patient calls reporting an out-of-stock situation.
4. Recommend that patients use medfinder to locate stock before calling the office — this reduces unnecessary phone burden on your staff.

Directing Patients to medfinder

medfinder is a paid prescription-finding service that calls pharmacies on behalf of patients to check stock, then texts them the results. Practices can recommend it as a first step before calling the office when patients can't fill a travoprost prescription. Visit medfinder.com/providers to learn more about supporting your patients. See also How to Help Your Patients Find Travatan Z in Stock for a companion provider guide.